Literature DB >> 12507887

Low frequency of FAS mutations in Reed-Sternberg cells of Hodgkin's lymphoma.

Ewerton M Maggio1, Anke Van Den Berg, Debora de Jong, Arjan Diepstra, Sibrand Poppema.   

Abstract

Reed-Sternberg (RS) cells, the neoplastic elements of Hodgkin's lymphoma (HL), usually lack B-cell receptor expression. Normal germinal center B cells, with lack of or low-affinity B-cell receptor expression, are eliminated via FAS-induced apoptosis. RS cells express FAS, but are rescued from apoptosis by a transforming event. It is known that HL-derived cell lines are resistant to FAS-mediated apoptosis. To investigate potential causes for this resistance, FAS mutations and c-FLIP expression were studied in four HL-derived cell lines and 20 cases of HL. L1236 was found to have a splice donor site mutation in intron 7 that resulted in an aberrantly spliced FAS transcript. Screening of microdissected RS cells revealed loss of heterozygosity for a known exon 7 polymorphism in two of six informative cases indicating loss of one FAS allele. In one of the two cases with loss of heterozygosity a hemizygous mutation was detected in exon 9. c-FLIP expression was observed in all HL cell lines and in RS cells of all HL cases. Our data show that FAS mutations are rare and suggest that overexpression of c-FLIP, which was present in all cases, is involved in the resistance to FAS-mediated apoptosis.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12507887      PMCID: PMC1851130          DOI: 10.1016/S0002-9440(10)63795-9

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  49 in total

1.  Genomic imbalances including amplification of the tyrosine kinase gene JAK2 in CD30+ Hodgkin cells.

Authors:  S Joos; M Küpper; S Ohl; F von Bonin; G Mechtersheimer; M Bentz; P Marynen; P Möller; M Pfreundschuh; L Trümper; P Lichter
Journal:  Cancer Res       Date:  2000-02-01       Impact factor: 12.701

Review 2.  Death-receptor contribution to the germinal-center reaction.

Authors:  M van Eijk; T Defrance; A Hennino; C de Groot
Journal:  Trends Immunol       Date:  2001-12       Impact factor: 16.687

3.  Alterations of Fas (APO-1/CD95) gene in transitional cell carcinomas of urinary bladder.

Authors:  S H Lee; M S Shin; W S Park; S Y Kim; S M Dong; J H Pi; H K Lee; H S Kim; J J Jang; C S Kim; S H Kim; J Y Lee; N J Yoo
Journal:  Cancer Res       Date:  1999-07-01       Impact factor: 12.701

4.  CD95 (APO-1/Fas) mutations in childhood T-lineage acute lymphoblastic leukemia.

Authors:  C Beltinger; E Kurz; T Böhler; M Schrappe; W D Ludwig; K M Debatin
Journal:  Blood       Date:  1998-05-15       Impact factor: 22.113

5.  Resistance to CD95-mediated apoptosis through constitutive c-FLIP expression in a non-Hodgkin's lymphoma B cell line.

Authors:  M Irisarri; J Plumas; T Bonnefoix; M C Jacob; C Roucard; M A Pasquier; J J Sotto; A Lajmanovich
Journal:  Leukemia       Date:  2000-12       Impact factor: 11.528

6.  Germline FAS gene mutation in a case of ALPS and NLP Hodgkin lymphoma.

Authors:  Anke van den Berg; Ewerton Maggio; Arjan Diepstra; Debora de Jong; Johan van Krieken; Sibrand Poppema
Journal:  Blood       Date:  2002-02-15       Impact factor: 22.113

7.  Lymphoproliferation disorder in mice explained by defects in Fas antigen that mediates apoptosis.

Authors:  R Watanabe-Fukunaga; C I Brannan; N G Copeland; N A Jenkins; S Nagata
Journal:  Nature       Date:  1992-03-26       Impact factor: 49.962

8.  Common and differential chemokine expression patterns in rs cells of NLP, EBV positive and negative classical Hodgkin lymphomas.

Authors:  Ewerton M Maggio; Anke Van Den Berg; Lydia Visser; Arjan Diepstra; Joust Kluiver; Roelke Emmens; Sibrand Poppema
Journal:  Int J Cancer       Date:  2002-06-10       Impact factor: 7.396

9.  Clonal deleterious mutations in the IkappaBalpha gene in the malignant cells in Hodgkin's lymphoma.

Authors:  B Jungnickel; A Staratschek-Jox; A Bräuninger; T Spieker; J Wolf; V Diehl; M L Hansmann; K Rajewsky; R Küppers
Journal:  J Exp Med       Date:  2000-01-17       Impact factor: 14.307

10.  FLICE-inhibitory protein is a key regulator of germinal center B cell apoptosis.

Authors:  A Hennino; M Bérard; P H Krammer; T Defrance
Journal:  J Exp Med       Date:  2001-02-19       Impact factor: 14.307

View more
  7 in total

1.  Expression of the cellular FLICE-inhibitory protein (c-FLIP) protects Hodgkin's lymphoma cells from autonomous Fas-mediated death.

Authors:  A Dutton; J D O'Neil; A E Milner; G M Reynolds; J Starczynski; J Crocker; L S Young; P G Murray
Journal:  Proc Natl Acad Sci U S A       Date:  2004-04-19       Impact factor: 11.205

2.  cIAP2 is highly expressed in Hodgkin-Reed-Sternberg cells and inhibits apoptosis by interfering with constitutively active caspase-3.

Authors:  Horst Dürkop; Burkhard Hirsch; Corinna Hahn; Harald Stein
Journal:  J Mol Med (Berl)       Date:  2005-11-25       Impact factor: 4.599

Review 3.  Genomic alterations in Hodgkin's lymphoma.

Authors:  Marc A Weniger; Thomas F E Barth; Peter Möller
Journal:  Int J Hematol       Date:  2006-06       Impact factor: 2.490

4.  A high throughput experimental approach to identify miRNA targets in human cells.

Authors:  Lu Ping Tan; Erwin Seinen; Gerben Duns; Debora de Jong; Ody C M Sibon; Sibrand Poppema; Bart-Jan Kroesen; Klaas Kok; Anke van den Berg
Journal:  Nucleic Acids Res       Date:  2009-09-04       Impact factor: 16.971

Review 5.  Contribution of the Epstein Barr virus to the molecular pathogenesis of Hodgkin lymphoma.

Authors:  G Kapatai; P Murray
Journal:  J Clin Pathol       Date:  2007-12       Impact factor: 3.411

6.  c-FLIP mediates resistance of Hodgkin/Reed-Sternberg cells to death receptor-induced apoptosis.

Authors:  Stephan Mathas; Andreas Lietz; Ioannis Anagnostopoulos; Franziska Hummel; Burkhard Wiesner; Martin Janz; Franziska Jundt; Burkhard Hirsch; Korinna Jöhrens-Leder; Hans-Peter Vornlocher; Kurt Bommert; Harald Stein; Bernd Dörken
Journal:  J Exp Med       Date:  2004-04-12       Impact factor: 14.307

7.  Analysis of the mutational landscape of classic Hodgkin lymphoma identifies disease heterogeneity and potential therapeutic targets.

Authors:  Elena Mata; Antonio Díaz-López; Ana M Martín-Moreno; Margarita Sánchez-Beato; Ignacio Varela; María J Mestre; Carlos Santonja; Fernando Burgos; Javier Menárguez; Mónica Estévez; Mariano Provencio; Beatriz Sánchez-Espiridión; Eva Díaz; Carlos Montalbán; Miguel A Piris; Juan F García
Journal:  Oncotarget       Date:  2017-11-30
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.